Tilarginine
- Generic Name
- Tilarginine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H16N4O2
- CAS Number
- 17035-90-4
- Unique Ingredient Identifier
- 27JT06E6GR
- Background
Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.
- Associated Conditions
- -
- Associated Therapies
- -
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 36
- Registration Number
- NCT05660083
- Locations
- 🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 130
- Registration Number
- NCT03625349
- Locations
- 🇺🇸
VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States
Phase Ib of L-NMMA and Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03236935
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation
- Conditions
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT03066115
- Locations
- 🇺🇸
University of Wisconsin, Madison, Madison, Wisconsin, United States
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02834403
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Plasma Triglyceride Extraction by The Muscle
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT01860911
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 70
- Registration Number
- NCT01744236
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Effect of DPP4 Inhibition on Growth Hormone Secretion
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 44
- Registration Number
- NCT01701973
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Pathophysiology of Cardiometabolic Risk Factors in African Americans
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT01122407
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 12
- Registration Number
- NCT00708357
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.